Daré Bio's FDA Approved Drug Will Make Us Rich --- $DARE //// Let me show you how to sift through Daré Bioscience’s income statement and statement of cash flows to understand their financials really well. We can run my discounted cash flow model together to see if the stock is a buy or a sell. We are also analyzing the financial ratios to see how they compare to their competitors. We will look at the debt of the company and equity. We will also calculate the WACC (weighted average cost of capital) so we can discount the future cash flows. Let's also look to see if the company is paying a dividend.

0:00 Opening
0:24 High Level Company Detail
2:54 Financial Review
10:10 Capital Structure
10:26 Valuation Results
11:59 More info
13:52 Financial Ratios
14:27 Competitor Analysis
15:03 Closing

This video is not investment advice. It is for entertainment purposes only. It is my opinion using publicly available information. Seek a duly licensed professional for investment advice.

- Cerulean was a cancer drug company from 2005 until 2017 then it merged with Daré. The new entity was named Dare Bioscience and the ticker was changed to DARE. When this merger occurred the new entity did a 1 for 10 reverse stock split. Cerulean initially IPO'd in 2014 for $7 per share but it struggled ever since going public. Its kidney cancer drug failed a Phase 2 trial which was the 2nd failed trial. The first failed trial occurred before the company went public. Without this merger Cerulean would have eventually dissolved its entire business. The new entity focuses on the development of products in women's health primarily contraception, fertility also vaginal & sexual health.

- The Bill & Melinda gates foundation has donated a lot of money to Dare in order for the company to move forward with it R&D. One of its products is a hormone free contraceptive device called Ovaprene. Drug company Bayer signed an exclusive licensing agreement for this product. If things go as planned Dare will receive $310mn in milestone pmts plus royalties.

- Its bacterial vaginal product has received FDA appr (zah-she-AH-toe). Its hormone therapy product is in phase II. Its sildenafil cream is in phase 2. Men use Sildenafil for erectile dysfunction. Dare's cream is for FSAD which stands for female sexual arousal disorder. It will be first product to treat FSAD. FSAD can occur in women of any age but it is more common as woman get older and even more prevalent for pre-menopausal women. It has several more drugs in Phase I or in pre-clinical stage.

- The company is headquartered in San Diego, CA and was founded in 2005

- The new entity with the ticker DARE started trading in 2017 and can be found on the Nasdaq & Deutsche Borse

SUBSCRIBE:
Please subscribe to my channel:
[ Ссылка ]

MEMBERSHIP LEVELS:
If you'd like me to do a: (i) custom valuation for a stock of your choice for $9.99 per month or (iii) show your support for this channel for $0.99 per month, you can become a member by clicking on the link below:
[ Ссылка ]

MORE STOCK VIDEOS:
AbCellera: [ Ссылка ]
Acasti Pharma: [ Ссылка ]
ADMA Biologics: [ Ссылка ]
Daré Bioscience: [ Ссылка ]
Entheon Biomedical: [ Ссылка ]
Exelixis: [ Ссылка ]
Forte Biosciences: [ Ссылка ]
Incyte: [ Ссылка ]
Moderna: [ Ссылка ]
ObsEva: [ Ссылка ]
Ocugen: [ Ссылка ]
Onconova Therapeutics: [ Ссылка ]
Regeneron: [ Ссылка ]
Royalty Pharma: [ Ссылка ]
Sesen Bio: [ Ссылка ]
Vertex: [ Ссылка ]
Vaxart: [ Ссылка ]

CONTACT:
financial.business.consultant.sr@gmail.com

Discounted cash flow (DCF) is a valuation method used to estimate the value of an investment based on its future cash flows. DCF analysis attempts to figure out the value of an investment today, based on projections of how much money it will generate in the future.

This video is not investment advice. It is for entertainment purposes only. It is my opinion using publicly available information. Seek a duly licensed professional for investment advice.

свернуть